摘要
目的：研究原发性肺鳞癌和腺癌ＭＤＲ１Ｐ－糖蛋白（Ｐ－ｇｐ）的表达及其临床意义。方法：应用ＪＳＢ－１Ｐ－ｇｐ单克隆抗体ＬＳＡＢ免疫组化方法，检测１０１例肺癌组织中Ｐ－ｇｐ的表达。结果：１０１例肺癌组织中，３１例（３０．７％）Ｐ－ｇｐ阳性表达，腺癌中Ｐ－ｇｐ阳性表达率（４３．８％）显著高于鳞癌（１８．９％）（Ｐ＜０．０５）。Ｐ－ｇｐ表达与鳞癌组织学分级有显著关系，高分化组Ｐ－ｇｐ阳性表达率显著高于低分化组；在肺腺癌，Ｐ－ｇｐ表达与肿瘤大小及患者预后有显著关系。结论：Ｐ－ｇｐ是肺癌产生耐药的主要原因之一；Ｐ－ｇｐ表达是肺腺癌预后不良的指标，而对鳞癌预后意义不明显。
Objective:To study the expression of P glycoprotein(P gp)in squamous carcinoma and adenocarcinoma of lung and to discuss its clinical significance Methods:101 cases of lung cancer was stained with JSB 1 P gp monoclonal antibody by LSAB method Results:Out of 101 lung carcinomas,31(30 7%)were positive in the expression of P gp The positive rate(43 8%)in adenocarcinoma was significantly higher than that (18 9%)in squamous carcinoma Expression of P gp was correlated with histological grade of squamous carcinoma;in adenocarcinoma,P gp expression was correlated with the size of tumor and prognosis of patients Conclusion:Detectable P gp is the cause of drug resistance in lung cancer and P gp expression appears to be an adverse prognostic factor,but there is no obvious correlation between P gp expression and prognosis of squamous carcinoma
出处
《滨州医学院学报》
1999年第2期109-110,共2页
Journal of Binzhou Medical University
关键词
肺肿瘤
P-糖蛋白
预后
表达
pulmonary neoplasms
P glycoprotein
prognosis
